Insilico Medicine has nominated ISM9546, a generative AI-designed oral molecular glue degrader targeting VAV1, a protein long considered inaccessible to conventional small molecules. In a rodent model of acute colitis, the compound reduced disease activity within days and improved histopathology scores by roughly 60%, outperforming a reference VAV1 degrader with no detected off-target protein loss. All data remain preclinical, with no stated timeline for human trials.
Key Points
- AI-designed VAV1 degrader cut colitis histopathology scores by 60%
- Targeted protein degradation reaches previously undruggable immune signaling nodes
- Peripherally restricted design limited brain exposure in toxicity studies
Longevity Analysis
Chronic low-grade inflammation driven by overactive immune signaling is among the more consistent accelerators of tissue decline, and VAV1 sits upstream of how immune cells decide to activate and proliferate. Removing a dysfunctional protein rather than blocking it represents a shift toward eliminating the source of interference at the molecular level, with the compound's calibrated half-life intended to preserve the body's capacity to mount an infection response. Whether the intestinal lining repair observed in rodents translates to durable benefit in humans remains unestablished, but the approach addresses inflammation where it originates rather than downstream of its consequences.
Original published by Longevity.Technology, by Kyle Umipig.